ANI Pharmaceuticals (NASDAQ: ANIP) posts preliminary 2025 results, 2026 view

Rhea-AI Filing Summary

ANI Pharmaceuticals, Inc. reported that it has issued a press release with select preliminary unaudited financial results for the fourth quarter and full fiscal year ended December 31, 2025, along with preliminary 2026 financial guidance. These figures are based on management estimates, have not been audited or reviewed by the company’s independent registered public accounting firm, and may change, potentially in a material way.

The company also noted that President & CEO Nikhil Lalwani will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, with an accompanying investor presentation furnished as an exhibit. The preliminary results and guidance, as well as the presentation materials, are provided as furnished information and are not deemed filed for liability purposes under the securities laws.

Insights

Equity research analyst

ANI shares preliminary 2025 results and 2026 guidance, but without audited figures.

ANI Pharmaceuticals is providing select preliminary unaudited financial results for Q4 and full-year 2025, together with preliminary guidance for 2026. Because these numbers are described as preliminary and based on management estimates, they serve mainly as an early indication of performance rather than final results.

The company emphasizes that its independent registered public accounting firm has not audited or reviewed these preliminary figures and that they may change, possibly in a material way. This caveat means any conclusions drawn from the information in the press release should be treated cautiously until full audited financial statements are available in later filings.

Management is also using the 44th Annual J.P. Morgan Healthcare Conference to share an investor presentation, which is furnished as an exhibit. Subsequent periodic reports that include audited results for the year ended December 31, 2025 will provide a firmer basis to understand ANI’s financial trajectory and how it aligns with the preliminary 2026 guidance.

0001023024FALSE00010230242026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 8-K 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): January 12, 2026

ANI PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware			001-31812			58-2301143
(State or other jurisdiction of incorporation)			(Commission File Number)			(I.R.S. Employer Identification No.)

210 Main Street West Baudette, Minnesota			56623
(Address of principal executive offices)			(Zip Code)

Registrant's telephone number, including area code: (218) 634-3500

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock			ANIP			Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02 Results of Operations and Financial Condition

On January 12, 2026, ANI Pharmaceuticals, Inc. (the “Company”) issued a press release announcing select preliminary unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025, as well as preliminary 2026 financial guidance. A copy of the press release is furnished herewith as Exhibit 99.1.*

The selected financial results are based on preliminary unaudited information and management estimates, are not a comprehensive statement of the Company’s financial results for either the fourth quarter or fiscal year ended December 31, 2025 and are subject to change. Such changes may be material. Our independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or provide any other form of assurance with respect to, these preliminary results.

In addition, on January 13, 2026, Nikhil Lalwani, President & CEO of the Company, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California. A copy of the investor presentation is attached as Exhibit 99.2 hereto and incorporated herein by reference.*

Item 7.01 Regulation FD Disclosure

The information included under Item 2.02 of this Current Report on Form 8-K is incorporated into this Item 7.01 by reference.*

Item 9.01 Exhibits

(d)Exhibits

Exhibit No.			Description
99.1			Press Release of the Company, dated January 12, 2026
99.2			Investor Presentation, dated January 2026
104			Cover Page Interactive Data File (embedded with the Inline XBRL document)

*The information in Item 2.02 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 12, 2026			ANI PHARMACEUTICALS, INC.
			By:			/s/ Stephen P. Carey
			Name:			Stephen P. Carey
			Title:			Senior Vice President Finance and Chief Financial Officer

FAQ

What did ANI Pharmaceuticals (ANIP) disclose in this 8-K?

ANI Pharmaceuticals disclosed that it issued a press release with select preliminary unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025, along with preliminary 2026 financial guidance, and furnished the related documents as exhibits.

Are ANI Pharmaceuticals’ preliminary 2025 results audited?

No. The company states that the selected financial results are based on preliminary unaudited information and management estimates, and that its independent registered public accounting firm has not conducted an audit or review of these preliminary results.

What guidance did ANI Pharmaceuticals provide for 2026?

ANI Pharmaceuticals reports that it has issued preliminary 2026 financial guidance in its press release for the year ended December 31, 2025. Specific figures are not included in this excerpt but are contained in the furnished press release.

How might ANI Pharmaceuticals’ preliminary results change?

The company notes that its selected financial results are based on preliminary unaudited information and are subject to change, and explicitly states that such changes may be material once final audited results are prepared.

What event is ANI Pharmaceuticals’ CEO participating in?

President & CEO Nikhil Lalwani is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California, with an investor presentation furnished as Exhibit 99.2.

Are the ANI Pharmaceuticals exhibits considered filed with the SEC?

The company explains that the information in Item 2.02 and the related exhibits are furnished, not filed, and therefore are not subject to Section 18 liability or automatically incorporated into other Securities Act or Exchange Act filings.